GlassScriptPhysician profile
Renee E Robel
NPI 1205481017
$4,478.65
in general payments reported to CMS, 2019-2025
27 companies · $725 in 2025
The $725 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $778 · 2023: $1,734 · 2024: $965 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,422.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,004.29 | 2021-2025 | Watchman, Resonate El Icd Vr, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $456.89 | 2021-2023 | Xarelto |
| Pfizer INC. | $371.76 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $351.33 | 2022-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $277.45 | 2023-2024 | Optimizer, Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.04 | 2022-2025 | Jardiance |
| Itamar Medical INC | $212.62 | 2023-2025 | Watchpatone |
| Amgen INC. | $185.77 | 2022-2025 | Repatha |
| Merck Sharp & Dohme LLC | $176.63 | 2022-2023 | Verquvo |
| Cvrx, INC. | $154.89 | 2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $128.19 | 2021-2024 | Farxiga, Brilinta |
| Kiniksa Pharmaceuticals International, Plc | $127.15 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $106.34 | 2023-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $100.00 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lexicon Pharmaceuticals, INC. | $76.96 | 2023-2024 | Inpefa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $76.84 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $64.59 | 2022-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $64.51 | 2023-2025 | |
| Medtronic, INC. | $55.57 | 2022-2023 | Cobalt Dr Mri Surescan |
| Bridgebio Pharma, INC. | $43.68 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $39.33 | 2025 | Onpattro |
| Innovation Technologies INC | $38.58 | 2023 | Irrisept |
| Irhythm Technologies, INC. | $31.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.29 | 2023 | |
| Pharmacosmos Therapeutics INC. | $24.99 | 2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $24.21 | 2024 | Evkeeza |
| Lilly USA, LLC | $21.79 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Robel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.